AGA clinical practice update: De-prescribing PPIs reduces costs, risks for adverse events

AGA clinical practice update: De-prescribing PPIs reduces costs, risks for adverse events

The AGA has issued a clinical practice update on de-prescribing proton pump inhibitors, according to an article in Gastroenterology.“Although PPIs are the treatment of choice for the management of acid-mediated upper gastrointestinal conditions, these agents are being used increasingly for less clear indications and for indeterminate durations,” Laura E. Targownik, MD, MSHS, a gastroenterologist at…

AHA: Addressing ‘undiagnosed’ NAFLD could mitigate CVD risk

AHA: Addressing ‘undiagnosed’ NAFLD could mitigate CVD risk

Nonalcoholic fatty liver disease remains widely undiagnosed, yet early identification and treatment could mitigate long-term risk for CVD, according to a new American Heart Association scientific statement.Nonalcoholic fatty liver disease (NAFLD) is believed to affect at least 25% of adults worldwide, according to the AHA. Unless specific testing is done to identify NAFLD, the condition…

Alcohol-associated liver disease mortality on rise, surged during pandemic

Alcohol-associated liver disease mortality on rise, surged during pandemic

Alcohol-associated liver disease mortality rates increased each year from 2017 to 2020 and accelerated during the COVID-19 pandemic, according to data published in Clinical Gastroenterology and Hepatology.“We have witnessed a persistent increase in mortality for over two decades now and have seen an acceleration in this trend since the onset of the COVID-19 pandemic,” Sasha…